Processing...

Biomarkers for precision therapy and prevention of type 2 diabetes

10 March 2020 | 2—5PM | Malmö

By defining novel biomarkers for an improved taxonomy of type 2 diabetes and its progression, RHAPSODY intends to open up new roads towards diabetes prevention and treatment, and accelerate the development of personalised diabetes care.

Four years into the project, the RHAPSODY team is eager to share its achievements with patient and healthcare communities in the Öresund region and welcomes all to a half-day symposium on March 10, 2020.

Agenda

Time
Title
Speaker
13.30
Registration
14.00
Welcome
Leif Groop
Lund University Diabetes Centre
RHAPSODY vice-coordinator
14.05
Diabetes care – a clinician`s point of view
Andreas Festa
Eli Lilly, diabetologist
14.20
Diabetes care - a patient's perspective
Anders Ekholm
Chair Greater Stockholm Diabetes Association
14.35
What does the Innovative Medicines Initiative do to help patients with diabetes?
Claire Varin
RHAPSODY industry coordinator, Servier Paris
14.45
The RHAPSODY project:
Biomarkers in type 2 diabetes
Bernard Thorens
RHAPSODY academic coordinator, Lausanne
15.15
Coffee break
15.45
A new diabetes patient sub-classification: what's next?
Emma Ahlqvist
Lund University Diabetes Centre
16.00
A new diabetes patient sub-classification: its application in RHAPSODY
Roderick Slieker
Leiden University Medical Center
16.15
Panel discussion
"Why does it matter?"
Moderator: Andreas Festa
Participants:
Claire Varin, Bernard Thorens, Anders Ekholm, Elizabeth Robertson (Diabetes UK), Karin Filipsson (Scania University Hospital), Steven Kahn (UW Medecine, RHAPSODY scientific advisor)
17.15
Wrap-up and conclusions, followed by mingle and open discussion
Claire Varin,
Bernard Thorens
18.30
End of the meeting

Venue


Jubileumsaula
Scania University Hospital
Jan Waldenströms gata 1
21428 Malmö, Sweden

Other information


» Free of charge
» Registration mandatory
Stacks Image p6845_n47
Stacks Image p6845_n398
Stacks Image p6845_n51
Stacks Image p6845_n349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.